NEW YORK, Jan. 11, 2019 /PRNewswire/ -- Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices, has launched a new investigation into recent recalls for valsartan and other angiotensin II receptor blockers that may have been contaminated with cancer-causing chemicals.
"Since June of 2018, dangerous impurities have been detected in active ingredients used to manufacture generic heart failure and high blood pressure drugs, including valsartan, irbesartan, and losartan," said Sandy A. Liebhard, a partner at Bernstein Liebhard LLP. "Our attorneys are committed to ensuring that the victims of these contaminated medications are fairly and fully compensated for all of their injury-related damages."
The firm is now offering free, no-obligation legal reviews to patients who were diagnosed with certain cancers or serious liver injuries after ingesting recalled valsartan, irbesartan, or losartan products.
What Patients Should Know About Recalls Involving Valsartan and other ARBs
According to the U.S. Food & Drug Administration (FDA), tests have detected trace amounts of N-Nitrosodimethylamine (NDMA) or N-Nitrosodiethylamine (NDEA) in the Active Pharmaceutical Ingredient (API) used to manufacture valsartan and other generic ARBs.
NDMA and NDEA are considered probable human carcinogens. Exposure to these chemicals may also cause liver damage.
Since June 2018, generic drug makers in the United States and more than 20 other countries have been forced to recall ARB medications, including:
- Valsartan in combination with Amlodipine
- Valsartan in combination with Hydrochlorothiazide (Valsartan HCT)
- Valsartan in combination with Amlodipine and Hydrochlorothiazide
The API used in the recalled medications was supplied by India-based Hetero Labs and Zhejiang Huahai Pharmaceuticals of China. According to the FDA, the chemicals are likely a byproduct of a production method utilized by these manufacturers since 2014.
Patients taking these ARBs should check with their pharmacist to determine if their medication was recalled. The FDA also maintains updated lists of valsartan products under recall, losartan medications under recall, and irbesartan products under recall at its website.
Patients with a recalled ARB should not stop taking their medication before they have obtained a replacement, as doing so could lead to serious adverse health consequences.
Learn More About Filing a Valsartan Lawsuit
Patients, or their surviving family members, may be entitled to compensation if they ingested a recalled valsartan, losartan, or irbesartan medication AFTER 2014 and were diagnosed with one of the following injuries:
- Liver Cancer
- Liver Injury with at least 3 Days Hospitalization
- Cancer of the intestines
- Rectal Cancer
- Colon Cancer
- Duodenal Cancer
- Small intestine cancer
- Stomach Cancer
- Kidney Cancer
- Bowel cancer
To learn if you qualify to file a valsartan lawsuit, please contact Bernstein Liebhard LLP by visiting the Firm's website, or by calling 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP has been named to The National Law Journal's "Plaintiffs' Hot List" 13 times and listed in The Legal 500 for 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2019 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
SOURCE Bernstein Liebhard LLP